In the last trading session, 1.0 million Prime Medicine Inc (NASDAQ:PRME) shares changed hands as the company’s beta touched 2.02. With the company’s per share price at $1.75 changed hands at -$0.04 or -2.23% during last session, the market valuation stood at $229.53M. PRME’s last price was a discount, traded about -372.57% off its 52-week high of $8.27. The share price had its 52-week low at $1.71, which suggests the last value was 2.29% up since then. When we look at Prime Medicine Inc’s average trading volume, we note the 10-day average is 1.49 million shares, with the 3-month average coming to 1.12 million.
Analysts gave the Prime Medicine Inc (PRME) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.17. If we narrow down to specifics, the data shows that 0 out of 5 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 1 recommended PRME as a Hold, 4 felt it is a Buy and 0 rated the stock as Underweight. Prime Medicine Inc’s EPS for the current quarter is expected to be -0.3.
Prime Medicine Inc (NASDAQ:PRME) trade information
Instantly PRME was in red as seen at the end of in last trading. With action -15.87%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -40.07%, with the 5-day performance at -15.87% in the red. However, in the 30-day time frame, Prime Medicine Inc (NASDAQ:PRME) is -32.56% down. Looking at the short shares, we see there were 18.04 million shares sold at short interest cover period of 17.29 days.
The consensus price target for the stock as assigned by Wall Street analysts is 17, meaning bulls need an upside of 89.71% from its current market value. According to analyst projections, PRME’s forecast low is 12 with 23 as the target high. To hit the forecast high, the stock’s price needs a -1214.29% plunge from its current level, while the stock would need to soar -585.71% for it to hit the projected low.
Prime Medicine Inc (PRME) estimates and forecasts
Year-over-year growth is forecast to reach 560.21% up from the last financial year.
Consensus estimates given by 9 financial analysts project the company’s revenue in the current quarter to hit an average of 3.43M. 9 analysts are of the opinion that Prime Medicine Inc’s revenue for the current quarter will be 3.39M. The company’s revenue for the corresponding quarters a year ago was 591k. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 480.77%. The estimates for the next quarter sales put growth at 0.00%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -124.13%. The 2025 estimates are for Prime Medicine Inc earnings to increase by 27.27%, but the outlook for the next 5-year period is at 10.91% per year.
PRME Dividends
Prime Medicine Inc is expected to release its next quarterly earnings report on 2025-Feb-27.
Prime Medicine Inc (NASDAQ:PRME)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 23.91% of Prime Medicine Inc shares while 59.05% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 77.60%. There are 59.05% institutions holding the Prime Medicine Inc stock share, with ALPHABET INC. the top institutional holder. As of 2024-06-30, the company held 12.6375% of the shares, roughly 15.06 million PRME shares worth $77.42 million.
ARK INVESTMENT MANAGEMENT LLC holds the second largest percentage of outstanding shares, with 5.1404% or 6.13 million shares worth $31.49 million as of 2024-06-30.
Among Mutual Funds, the top two as of Jan 31, 2025 were ARK ETF Tr-ARK Genomic Revolution ETF and ARK ETF Tr-ARK Innovation ETF . With 2.37 shares estimated at $4.15 million under it, the former controlled 1.81% of total outstanding shares. On the other hand, ARK ETF Tr-ARK Innovation ETF held about 1.67% of the shares, roughly 2.19 shares worth around $3.83 million.
